Table 1.
Baseline Characteristics of 85 Patients (Group 1) With MEN2 Associated PHEO With Subclassification of Patients With MEN2A and MEN2B
| Patient Demographics | MEN2A (n = 70) | MEN2B (n = 15) |
|---|---|---|
| Sex | ||
| Male | 26 (37%) | 5 (33%) |
| Female | 44 (63%) | 10 (67%) |
| Race | ||
| Caucasian | 59 (84%) | 10 (67%) |
| Other | 11 (16%) | 5 (33%) |
| Age at PHEO diagnosis, ya | 34 (17–60) | 25 (18–40) |
| Age at MTC diagnosis, ya | 26 (10–60) | 22 (8–39) |
| MTC tumor size, cma | 1.5 (0.5–6) | 1.8 (0.9–4.5) |
| PHEO tumor size, cma | 3.8 (1–14) | 2.5 (1–6.4) |
| Family history of MTC | 55 (79%) | 3 (20%) |
| Family history of PHEO | 45 (64%) | 2 (13%) |
| PHEO diagnosis secondary to screening | 48 (69%) | 9 (60%) |
| Median follow-up time for PHEO, mo | 119 (0–527) | 57 (1–251) |
| Bilateral PHEO | 51 (73%) | 10 (67%) |
| Synchronous | 43 (84%) | 7 (70%) |
| Metachronous | 8 (16%) | 3 (30%) |
a
Data represent median (minimum-maximum).